BeOne Medicines Ltd., formerly known as BeiGene, Ltd., is a multinational biopharmaceutical company specializing in oncology. Founded in 2010 by John V. Oyler and Xiaodong Wang, it focuses on discovering, developing, and commercializing innovative cancer treatments, including targeted therapies and immunotherapies for hematological malignancies and solid tumors.
Headquartered in Cambridge, Massachusetts, with additional key locations in Basel, Switzerland, Beijing, China, and operations across six continents in over 45 countries, the company employs approximately 12,000 people. It trades publicly on Nasdaq (ONC), SEHK (6160), and SSE (688235).
Key commercial products include BRUKINSA (zanubrutinib), a BTK inhibitor for blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody for solid tumors and blood cancers; and SYLVANT for multicentric Castleman disease. BeOne advances a broad pipeline of over 40 clinical and commercial-stage assets through internal capabilities, partnerships, and a global manufacturing network, including sites supporting oral solid dosage production.
In the chemical industry context, it develops small-molecule drugs and maintains pharmaceutical manufacturing facilities to produce active pharmaceutical ingredients and formulations for global distribution.
To provide comprehensive coverage, we aggregate data and news under the name BeOne Medicines, encompassing the following company names, divisions, and related entities:
BeiGene, Ltd., BeiGene, and 百濟神州有限公司.
This list encompasses current and former names, alternate names, and key divisions associated with BeOne Medicines, ensuring you can easily find all relevant information under a single, unified profile.
